1-3 of 3
Jérôme Fayette
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma

Aaron R. Hansen, Carlos A. Gomez-Roca, Debbie G. J. Robbrecht, Loic Verlingue, Antoine Italiano, Julie E. Bauman, Neeltje Steeghs, Hans Prenen, Jérôme Fayette, James Spicer, Jiaxin Niu, Christin Habigt, Meike Schneider, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Daniela Schmid, Christophe Boetsch, Jehad Charo, Anton Kraxner, Volker Teichgräber, Nino Keshelava, Marcelo R. Bonomi
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (24): 5540–5547.
https://doi.org/10.1158/1078-0432.CCR-24-1562
Published: 16 December 2024
View article titled, Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Open the PDF for Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Sophie Wildsmith, Weimin Li, Song Wu, Ross Stewart, Nassim Morsli, Rajiv Raja, Qu Zhang, Jiabu Ye, Philip He, Jagdish Shetty, Alejandro Yovine, Nicholas Holoweckyj, Katia Real, Jill Walker, Magdalena Wrona, Melissa de los Reyes, Craig Barker, Jessica Whiteley, Robert Haddad, Lisa Licitra, Robert Ferris, Jérôme Fayette, Dan P. Zandberg, Lillian L. Siu, Ricard Mesía
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (11): 2066–2074.
https://doi.org/10.1158/1078-0432.CCR-22-2765
Published: 01 June 2023
View article titled, Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Open the PDF for Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

Robert L. Ferris, Lisa Licitra, Jerome Fayette, Caroline Even, George Blumenschein, Jr, Kevin J. Harrington, Joel Guigay, Everett E. Vokes, Nabil F. Saba, Robert Haddad, Shanmugasundaram Ramkumar, Jeffery Russell, Peter Brossart, Makoto Tahara, A. Dimitrios Colevas, Fernando Concha-Benavente, Mark Lynch, Li Li, Maura L. Gillison
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (17): 5221–5230.
https://doi.org/10.1158/1078-0432.CCR-18-3944
Published: 03 September 2019
View article titled, Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use
Open the PDF for Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use in another window
Includes: Supplementary data